WASHINGTON, DC--(Marketwire - March 2, 2010) - Diaceutics, an international consulting firm that advises pharmaceutical companies on the development of targeted therapies (personalized medicine), has appointed Brent Vose, Ph.D. -- most recently the vice president and head of oncology and infection therapy with responsibility for personalized medicine, AstraZeneca -- as chairman of its board of directors.
"Diaceutics is privileged to have an individual as respected and experienced as Brent to lead our board," said Peter Keeling, chief executive officer of Diaceutics. "His broad understanding of therapeutic research, development -- and the entire therapeutic life cycle planning process -- brings invaluable perspective and insight to Diaceutics as we focus on helping pharmaceutical companies successfully develop companion diagnostic strategies to better target therapies."
Dr. Vose is an immunologist and pharmacist by training with broad drug development experience in cancer, infection and cardiovascular medicine. In his most recent position he led the team responsible for overall strategy in infection and cancer product development, with special responsibility for personalized medicine approaches across all therapy areas.
He graduated in Pharmacy from the University of Nottingham and later received a Ph.D. in tumor immunology. He was involved in academic research at the Patterson Cancer Research Laboratories, Christie Hospital Manchester, England; the Karolinska Institute, Sweden; and The National Cancer Institute, U.S.
Dr. Vose joined ICI Research in 1982 -- its pharmaceutical business later merged with AstraZeneca. During his career he has led teams responsible for the development of cancer products such as CASODEX (prostate), ARIMIDEX (breast), and TOMUDEX (colon). He also led the team overseeing the development of the lipid-lowering drug CRESTOR.
Diaceutics (www.diaceutics.com) provides pharmaceutical industry leaders with the foundation and operational structure needed to effectively develop and commercialize targeted therapies to better meet patients' needs and to improve overall return on investment. Diaceutics is an international change management and consulting firm specializing in personalized medicine with a mission to build bridges between pharmaceutical and diagnostic players.
Contact Information:
Contact:
Mollie Roth, Esq.,
Corporate Counsel, VP of Business Development
202-280-5887